Key Points
- Insider sale: Cellebrite CRO Marcus Jewell sold 12,562 shares at an average price of $11.24, worth approximately $141,197. He retained 427,128 shares after the transaction.
- Analyst outlook: Analysts lowered their price targets, but the stock maintains a “Moderate Buy” consensus with an average target of $16.70. Five analysts rate it Buy, while one rates it Sell.
- Stock performance: CLBT opened at $11.49, compared with a 52-week range of $9.58 to $19.98. Institutional investors own approximately 45.88% of the company.
Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) CMO David Nicholas Gee sold 2,198 shares of Cellebrite DI stock in a transaction on Friday, August 21st. The stock was sold at an average price of $11.24, for a total transaction of $24,705.52. Following the completion of the transaction, the chief marketing officer owned 139,604 shares in the company, valued at $1,569,148.96. This trade represents a 1.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
David Nicholas Gee also recently made the following trade(s):
- On Wednesday, August 12th, David Nicholas Gee sold 230 shares of Cellebrite DI stock. The shares were sold at an average price of $16.07, for a total transaction of $3,696.10.
Cellebrite DI Stock Performance
Shares of NASDAQ:CLBT opened at $11.49 on Tuesday. The company has a market cap of $2.87 billion, a P/E ratio of 52.23, a P/E/G ratio of 1.53 and a beta of 1.18. The stock's 50-day moving average is $14.24 and its 200-day moving average is $13.83. Cellebrite DI Ltd. has a 52-week low of $9.58 and a 52-week high of $19.98.
Analysts Set New Price Targets
CLBT has been the topic of a number of research analyst reports. Lake Street Capital lowered their target price on Cellebrite DI from $21.00 to $15.00 and set a "buy" rating on the stock in a report on Friday, August 14th. Weiss Ratings lowered Cellebrite DI from a "hold (c-)" rating to a "sell (d+)" rating in a report on Thursday, August 13th. DA Davidson reduced their price objective on Cellebrite DI from $22.00 to $15.00 and set a "buy" rating for the company in a research report on Friday, August 14th. JPMorgan Chase & Co. lowered their price objective on shares of Cellebrite DI from $20.00 to $16.00 and set an "overweight" rating on the stock in a research note on Friday, August 14th. Finally, Needham & Company LLC dropped their target price on shares of Cellebrite DI from $15.00 to $12.50 and set a "buy" rating on the stock in a research report on Friday, August 14th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $16.70.
Check Out Our Latest Report on Cellebrite DI
Hedge Funds Weigh In On Cellebrite DI
Several large investors have recently added to or reduced their stakes in the company. Roubaix Capital LLC boosted its position in Cellebrite DI by 108.1% in the first quarter. Roubaix Capital LLC now owns 303,215 shares of the company's stock valued at $4,178,000 after buying an additional 157,536 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in shares of Cellebrite DI during the first quarter worth approximately $2,134,000. Principal Financial Group Inc. raised its stake in shares of Cellebrite DI by 33.9% in the first quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company's stock valued at $29,712,000 after acquiring an additional 545,334 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Cellebrite DI by 14.7% in the first quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company's stock valued at $39,420,000 after acquiring an additional 365,700 shares during the last quarter. Finally, Weiss Asset Management LP boosted its holdings in shares of Cellebrite DI by 3,485.3% in the 1st quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company's stock worth $26,180,000 after acquiring an additional 1,846,851 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company's stock.
About Cellebrite DI
(
Get Free Report)
Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.
The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
